Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimers disease
Josh Lichtman, medical director at Neuro Wellness Spa, not involved in the study, commented on the research for MNT
The question of lifelong GLP-1 therapy does not have a universal answer, as treatment duration depends on the indication, individual patient circumstances, and treatment goals
Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
The FDA-approved answer is yes3